Press Releases Archives - Page 3 of 47 - Philogen Spa

The Board of Directors Approves the Half-Yearly Financial Report at 30 June 2025 (Price sensitive) – Courtesy English Translation

Sep 23, 2025 | 2025, Investors, Press Releases

more details

Philochem AG Announces Completion of Antitrust Clearance and Closing of the OncoACP3 Licensing Agreement with RayzeBio, a Bristol Myers Squibb Company, With a Potential Value of up to $1.35 Billion Plus Royalties

Aug 18, 2025 | 2025, Investors, Press Releases

For more details

La controllata Philochem AG annuncia il completamento del processo autorizzativo antitrust e la conclusione dell’accordo di licenza OncoACP3 con RayzeBio, una società di Bristol Myers Squibb, con un valore potenziale fino a 1,35 miliardi di dollari più royalties.

Aug 18, 2025 | 2025, Investors, Press Releases

Per maggiori dettagli

Philogen Provides Update on Marketing Authorization Application for Nidlegy™ in the European Union

Jun 24, 2025 | 2025, Past Events, Press Releases

More details

La controllata Philochem AG ha concesso in licenza i diritti a livello mondiale su OncoACP3, un nuovo agente terapeutico e diagnostico per il trattamento del cancro alla prostata, a RayzeBio, società del gruppo Bristol-Myers Squibb, per un valore fino a 1,35 miliardi di dollari più royalties.

Jun 10, 2025 | 2025, Press Releases

More details

Philochem AG Announces the Licensing of Worldwide Rights to OncoACP3, a novel Radiopharmaceutical Therapeutic and Diagnostic Agent targeting Prostate Cancer, to RayzeBio, a Bristol-Myers Squibb Company, for a potential value of up to $1.35bn plus royalties.

Jun 10, 2025 | 2025, Press Releases

More details

« Older Entries

Next Entries »